1445873-19-7

Basic information

• Product Name: methyl 1-(((2S,5R,6R)-5-hydroxy-6-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)-5,6-dihydro-2H-pyran-2-yl)oxy)-6-phenyl-4-(tri-fluoromethyl)-1H-indole-2-carboxylate
• Synonyms: methyl 1-(((2S,5R,6R)-5-hydroxy-6-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)-5,6-dihydro-2H-pyran-2-yl)oxy)-6-phenyl-4-(tri-fluoromethyl)-1H-indole-2-carboxylate
• CAS NO: 1445873-19-7
• Molecular Weight: 547.528
• Mol File: 1445873-19-7.mol

Chemical Properties

• CAS DataBase Reference: methyl 1-(((2S,5R,6R)-5-hydroxy-6-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)-5,6-dihydro-2H-pyran-2-yl)oxy)-6-phenyl-4-(tri-fluoromethyl)-1H-indole-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 1-(((2S,5R,6R)-5-hydroxy-6-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)-5,6-dihydro-2H-pyran-2-yl)oxy)-6-phenyl-4-(tri-fluoromethyl)-1H-indole-2-carboxylate(1445873-19-7)
• EPA Substance Registry System: methyl 1-(((2S,5R,6R)-5-hydroxy-6-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)-5,6-dihydro-2H-pyran-2-yl)oxy)-6-phenyl-4-(tri-fluoromethyl)-1H-indole-2-carboxylate(1445873-19-7)

Safety Data

• Hazardous Substances Data: 1445873-19-7(Hazardous Substances Data)

Upstream product

• 1033614-58-2 6-O-(tetrahydropyran-2-yl)-4-O-mesyl-D-glucal 
• 1269802-97-2 methyl 1-hydroxy-6-phenyl-4-(trifluoromethyl)-1H-indole-2-carboxylate 

Downstream Products

• 1445873-20-0 methyl 6-phenyl-4-(trifluoromethyl)-1-(((2S,3R,4R,5R,6R)-3,4,5-trihydroxy-6-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)-1H-indole-2-carboxylate 
• 1445872-93-4 methyl 6-phenyl-4-(trifluoromethyl)-1-(((2S,3R,4R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)-oxy)-1H-indole-2-carboxylate 

Relevant articles and documents

Synthesis and biological evaluation of non-glucose glycoconjugated N-hydroyxindole class LDH inhibitors as anticancer agents

Inhibitors of human lactate dehydrogenase A (LDH-A) are promising therapeutic agents against cancer. The development of LDH-A inhibitors that possess cellular activities has so far proved to be particularly challenging, since the enzyme's active site is narrow and highly polar. In the recent past, we were able to develop a glucose-conjugated N-hydroxyindole-based LDH-A inhibitor designed to exploit the sugar avidity expressed by cancer cells (the Warburg effect). Herein we describe a structural modulation of the sugar moiety of this class of inhibitors, with the insertion of α-d-mannose, β-d-gulose, or β-N-acetyl-d-glucosamine portions in their structures. Their stereospecific chemical synthesis, which involves a substrate-dependent stereospecific glycosylation step, and their biological activity in reducing lactate production and proliferation in cancer cells are reported. Interestingly, the α-d-mannose conjugate displayed the best properties in the cellular assays, demonstrating an efficient antiglycolytic and antiproliferative activity in cancer cells. This journal is

INDOLE DERIVATIVES INHIBITORS OF ENZYME LACTATE DEHYDROGENASE (LDH)

The present invention encompasses compounds having general formula (I) able to inhibit the lactate production (lactic acid) involved in the angiogenesis of tumoral tissues, in the glycolytic metabolic process of tumoral cells, of immune system cells in asthmatic diseases, in vascular cells in the pulmonary hypertension, in the treatment of chronic back pain or hyperoxaluria, and in the process by which the parasites protozoan causing malaria obtain most of the necessary energy.

INDOLE DERIVATIVES INHIBITORS OF ENZYME LACTATE DEHYDROGENASE (LDH)

The present invention encompasses compounds having general formula (I) able to inhibit the lactate production (lactic acid) involved in the angiogenesis of tumoral tissues, in the glycolytic metabolic process of tumoral cells, of immune system cells in asthmatic diseases, in vascular cells in the pulmonary hypertension, in the treatment of chronic back pain or hyperoxaluria, and in the process by which the parasites protozoan causing malaria obtain most of the necessary energy